CC
CYTK icon

Centiva Capital’s Cytokinetics CYTK Stock Holding History

Centiva Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.63M Buy
55,000
+41,300
+301% +$2.62M 0.03% 322
2025
Q4 		$870K Hold
13,700
– – 0.01% 599
2025
Q3 		$753K Buy
+13,700
New +$564K 0.01% 551
2024
Q2 		– Sell
-10,000
Closed -$701K – 2148
2024
Q1 		$701K Buy
10,000
+9,500
+1,900% +$735K 0.02% 839
2023
Q4 		$41.7K Buy
+500
New +$18.1K ﹤0.01% 1655

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Centiva Capital's CYTK Position: Q1 2026 in Review

Centiva Capital opened a new position in Cytokinetics (CYTK) in Q1 2026: 3,000 shares worth $198K. The stake represents ﹤0.01% of the portfolio and ranks #1281 among its holdings. This is a return to the name: Centiva Capital previously reported a position in CYTK as recently as Q4 2024.

Centiva Capital first reported a position in CYTK in Q1 2023 and has held it in 8 quarters since. The position peaked at $1.16M in Q1 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Centiva Capital held 3,000 shares of Cytokinetics worth $198K as of Q1 2026.
  • Cytokinetics was a new Centiva Capital position in Q1 2026.
  • Cytokinetics made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #1281 holding.
  • Centiva Capital first reported a position in Cytokinetics in Q1 2023 and has held it in 8 quarters since.
  • Centiva Capital's Cytokinetics position peaked at $1.16M in Q1 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.